HeXem Bio

HeXem Bio's core technology focuses on rejuvenating aged Hematopoietic Stem Cells (HSCs), the cells responsible for creating all blood cells. The company utilizes a proprietary "Yolk Sac Method," which creates a synthetic niche that mimics the early developmental environment of HSCs, effectively restoring their youthful function. This process is designed to be scalable and reproducible. The primary preclinical product is a rejuvenated hematopoietic stem cell therapy intended to produce stronger white blood cells for improved immunity, healthier red blood cells for better organ function, and increased platelets for faster recovery. The initial target application is to improve outcomes for bone marrow transplant patients with blood cancer. However, the company sees broader potential to address age-related diseases connected to immunity, neurodegeneration, and organ decline.

The company operates on a business model centered on partnerships with healthcare providers and research institutions. These collaborations involve direct sales or partnership agreements for the use of its specialized stem cell therapies. HeXem Bio has raised significant seed funding, including a $10.4 million round in April 2026 led by Draper Associates with participation from SOSV and Seraphim Space Manager. After receiving an Orphan Drug Designation, the company held a successful Pre-IND meeting with the FDA in January 2026.